Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Marcos Oro-Ayude"'
Autor:
Diego Soto‐García, Marcos Oro‐Ayude, Carlos Álvarez, Sandra Martínez‐Fernandez, Carmen Couselo‐Rodríguez, Ángeles Flórez
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 1, Pp 280-282 (2024)
Abstract Pityriasis rubra pilaris (PRP) can be triggered by viruses, such as cytomegalovirus, Epstein‐Barr virus, varicella zoster, human immunodeficiency virus and, more exceptionally, SARS‐CoV‐2. We report an additional case of PRP following
Externí odkaz:
https://doaj.org/article/ae3e649311dd451db026130906577e2a
Autor:
Marcos Oro-Ayude, Hae Jin Suh-Oh, Victor Sacristán-Santos, Patricia Vázquez-Bartolomé, Ángeles Flórez
Publikováno v:
Case Reports in Dermatology, Vol 12, Iss 1, Pp 37-41 (2020)
Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastati
Externí odkaz:
https://doaj.org/article/65cac7a8d8934bcaa60b5613cfad6309
Autor:
Carmen Couselo-Rodríguez, Antonio Losada-Campa, Marcos Oro-Ayude, Alberto Pérez-Rodríguez, Ángeles Flórez
Publikováno v:
Medicina Clínica Práctica, Vol 5, Iss 1, Pp 100267- (2022)
Externí odkaz:
https://doaj.org/article/db7fb495f77c4bc1954c0376cba1fa2a
Autor:
Patricia Vázquez-Bartolomé, Victor Sacristán-Santos, Hae Jin Suh-Oh, Ángeles Flórez, Marcos Oro-Ayude
Publikováno v:
Case Reports in Dermatology
Case Reports in Dermatology, Vol 12, Iss 1, Pp 37-41 (2020)
Case Reports in Dermatology, Vol 12, Iss 1, Pp 37-41 (2020)
Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1984747068645f1cba55e3005872fe00
http://europepmc.org/articles/PMC7315375
http://europepmc.org/articles/PMC7315375
Autor:
Carmen Couselo‐Rodríguez, Ana Batalla, Beatriz González‐Sixto, Marcos Oro‐Ayude, Carlos Álvarez‐Álvarez, Lourdes Loidi, Ángeles Flórez
Publikováno v:
International journal of dermatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83ed1fb51b1d0ec8fbcb9b3bba48e5cb
https://pubmed.ncbi.nlm.nih.gov/35506490
https://pubmed.ncbi.nlm.nih.gov/35506490
Autor:
Alberto Pérez-Rodríguez, Marcos Oro-Ayude, Antonio Losada-Campa, Carmen Couselo-Rodríguez, Ángeles Flórez
Publikováno v:
Medicina Clínica Práctica, Vol 5, Iss 1, Pp 100267-(2022)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb2e463e8ebd60ee71ca7d8c3344a689
http://www.sciencedirect.com/science/article/pii/S2603924921000793
http://www.sciencedirect.com/science/article/pii/S2603924921000793
Autor:
Carmen Couselo-Rodríguez, Laura Mesa-Álvarez, Beatriz González-Sixto, Carlos Feal, Aquilina Ramírez, Marcos Oro-Ayude, Á. Flórez, Carlos Álvarez-Álvarez, A. Batalla, Miguel Devesa-Múgica
Publikováno v:
Pediatric dermatologyREFERENCES. 38(5)
Multifocal granular cell tumor is a poorly understood entity. Its importance lies in its association with several genetic disorders and the challenging distinction between multifocal and metastatic granular cell tumor. Herein, we report an unusual ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4739c0920a9ae186fa96d7348323e6
https://pubmed.ncbi.nlm.nih.gov/34561879
https://pubmed.ncbi.nlm.nih.gov/34561879
Autor:
Marcos Oro-Ayude, Ángeles Flórez, Carlos Feal, Jose Manuel Faraldo‐Lorenzo, Beatriz González-Sixto
Publikováno v:
Dermatologic therapyREFERENCES. 34(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9603889271dd08e07c14a2f18c4648
https://pubmed.ncbi.nlm.nih.gov/33210813
https://pubmed.ncbi.nlm.nih.gov/33210813
Autor:
Marta Feito, Raúl de Lucas, Lucía Quintana-Castanedo, Maria Jose Beato‐Merino, Marcos Oro-Ayude
Publikováno v:
Pediatric dermatologyREFERENCES. 37(5)
Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14-year-old patient being treated with nilotinib who developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0222aa72c6a6d4a88fb252e0394597e
https://pubmed.ncbi.nlm.nih.gov/32602176
https://pubmed.ncbi.nlm.nih.gov/32602176
Autor:
Laura Mesa-Álvarez, Carlos Álvarez-Álvarez, Queila Rodríguez-Jato, Marcos Oro-Ayude, Ángeles Flórez, Diego Soto-García, Carmen Couselo-Rodríguez, Beatriz González-Sixto, Carlos Feal
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cb16ec8566d598b78ef01b07c2c4739
https://doi.org/10.1016/j.jaad.2021.06.325
https://doi.org/10.1016/j.jaad.2021.06.325